Regulus Therapeutics Inc.
RGLS
주식 순위
#17368
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
주가
$8.16
마지막 동기화: 2025-06-26
시가총액
$234.57M
변동 (1일)
0.00%
변동 (1년)
-88.86%
국가
US
거래 Regulus Therapeutics Inc. (RGLS)
카테고리
Healthcare
의 시가총액 Regulus Therapeutics Inc.(RGLS)
시가총액: $234.57M
October 2026 기준으로 Regulus Therapeutics Inc.의 시가총액은 $234.57M입니다. 이는 당사 데이터에 따르면 Regulus Therapeutics Inc.이 세계에서 17368th번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2010부터 2026까지 Regulus Therapeutics Inc.의 시가총액 기록
